PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
SOUTH PLAINFIELD, N.J., Sept. 28, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr. Zeldis is the Chief Executive Officer of Celgene Global Health and the Chief Medical Officer of Celgene Corporation in Summit, New Jersey.
"We are honored to welcome Dr. Zeldis to PTC's Board of Directors," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "As an established leader in the development of therapies addressing high unmet medical need, Dr. Zeldis' guidance will be extremely valuable as PTC advances ataluren through the clinical and regulatory approval process."
Dr. Zeldis has been with Celgene since 1997; prior to his current role he served as Senior Vice President of Clinical Research and Medical Affairs. Prior to Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He is currently on the board of the Semorex Corporation, the New Jersey chapter of the Arthritis Foundation and the Castleman's Disease Organization. Dr. Zeldis attended Brown University for a B.A., M.S., followed by Yale University for a M.Phil., M.D., and Ph.D. in molecular biophysics and biochemistry (immunochemistry). He trained in internal medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Zeldis has published 121 peer reviewed articles and 24 reviews, book chapters, and editorials.
"PTC is an innovative company at an exciting juncture in the clinical development of ataluren, an investigational new drug, for nonsense-mediated Duchenne and Beckers muscular dystrophy and cystic fibrosis," said Dr. Zeldis. "I look forward to being a part of the next phase of the company's growth, and to working with PTC to support its broad pipeline in rare disorders, cancer and other areas of high unmet medical need."
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.